

**PROJECT NAME:**

Management of Patients Receiving Oral Systemic Anti-Cancer Therapy for Advanced Renal Cell Carcinoma

**JOINT WORKING PROJECT SUMMARY:**

The aim of this project will be to develop the management pathway for patients with renal cell carcinoma on oral Vascular Endothelial Growth Factor (VEGF) inhibitors that reduces waiting times and workload in outpatient clinics, and improves patient satisfaction.

The project will have 4 phases:

1. An audit of current management of patients receiving oral VEGF inhibitors in advanced renal cell carcinoma
2. Design a pathway that incorporates pharmacy education and management of patients receiving oral VEGF inhibitors in advanced renal cell carcinoma – pharmacy education on initiation of treatment, with a telephone assessment after 2 weeks
3. Implement new pathway – with the potential for a pharmacy telephone assessment clinic to reduce the number of outpatient appointments
4. Review of pathway and business case submission

**EXPECTED PATIENT OUTCOMES FOR THIS PROJECT:**

- Deliver a high-quality patient experience by ensuring that the management and review pathway for patients with renal cell carcinoma on oral VEGF inhibitors is clear, concise and provides equity of care to all patients
- Capture service data that will demonstrate the value of new model of care to patients and NHS e.g. patient satisfaction, reduced outpatient clinic waiting times/reduced number of hospital appointments, prudent resource allocation
- Establish a model for the clinical pathway for patients with renal cell carcinoma having treatment with VEGF inhibitors at Velindre Cancer Centre, reduced time in hospital outpatients, improve patients experience, which can be replicated in the outreach setting

**ANTICIPATED BENEFITS FOR PATIENTS**

- Improved understanding of their treatment and how to manage any toxicity related to them
- Continuity of care and dedicated advice service therefore improved patient experience and satisfaction
- Reduce number of hospital appointments

**ANTICIPATED BENEFITS FOR THE NHS:**

- Opportunity to test new method of managing patient using a MDT approach
- Learning that can be gained may be extrapolated to other therapeutic areas.
- Prudent more efficient use of resources ensuring patients are seen or reviewed by the appropriate member of the MDT team
- Raise profile of Velindre as centre of excellence

**ANTICIPATED BENEFITS FOR IPSEN:**

- Opportunity to work with NHS Wales through joint working initiative to build relationships and reputation
- Patients will receive appropriate Ipsen products if clinically indicated in accordance with local and national clinical guidelines

**PROJECT START DATE & DURATION:** July 2018, 2 years.

*Extended following agreement by both parties to March 2021 due to COVID-19.*

**CMX-GB-001356**

**Date of preparation: November 2022**